Skip to main content
. Author manuscript; available in PMC: 2025 Sep 1.
Published in final edited form as: Neurogastroenterol Motil. 2024 Jun 24;36(9):e14852. doi: 10.1111/nmo.14852

TABLE 2.

Baseline demographic in patients with and without GER+.

Overall (n = 129) GER− (n = 60) GER+ (n = 69) p-value

Age (years) 54.1 (17.5) 53.3 (18.3) 54.8 (16.8) 0.63
Sex (female) 84/128 (66%) 42 (70%) 42/68 (62%) 0.33
BMI (kg/m2) 27.6 (6.8) 25.5 (5.9) 29.4 (7.0) <0.01
Race (n = 137)
 Caucasian 84 (66%) 41 (68%) 43 (62%) 0.15
 African American 5 (4%) 4 (7%) 1 (1%)
 Asian 8 (6%) 4 (7%) 4 (6%)
 Hispanic 17 (13%) 8 (13%) 9 (13%)
 Native American 0 (0%) 0 (0%) 0 (0%)
 Unknown/other 15 (12%) 3 (5%) 12 (17%)
Total LCAT 33.0 (13.1) 32.9 (13.8) 33.1 (12.6) 0.91
LCAT symptom-specific anxiety 17.9 (9.2) 18.0 (9.6) 17.8 (9.1) 0.87
LCAT hypervigilance 15.1 (4.9) 14.8 (5.1) 15.3 (4.8) 0.56
Elevated LCAT ≥33 73 (57%) 35 (58%) 38 (55%) 0.71
PROMIS anxiety, n = 127 17.2 (7.4) 17.5 (7.6) 16.9 (7.3) 0.61
PROMIS anxiety ≥20 (moderate/severe anxiety) 49/127 (39%) 26 (43%) 23/67 (34%) 0.30
PROMIS depression, n = 126 14.8 (7.6) 15.5 (7.6) 14.2 (7.6) 0.33
PROMIS depression >22 (moderate/severe depression) 24/126 (19%) 13/60 (22%) 11/66 (17%) 0.48
ICQ helplessness 11.2 (4.3) 11.3 (4.0) 11.1 (4.6) 0.75
ICQ acceptance 15.2 (3.9) 14.8 (4.0) 15.5 (3.9) 0.32
ICQ perceived benefits 12.6 (4.7) 12.7 (4.8) 12.5 (4.7) 0.85
NEQOL, n = 128 31.7 (14.5) 31.2 (14.3) 32.2 (14.8) 0.71
VHI, n = 125 22.4 (25.5) 21.5 (23.1) 23.1 (27.5) 0.73
RSI, n = 126 21.8 (10.4) 20.9 (10.5) 22.6 (10.2) 0.34
GerdQ 8.9 (2.8) 8.2 (2.7) 9.6 (2.7) <0.01
AET prolonged wireless pH monitoring off PPI, n = 77 8.2 (7.9) 2.5 (2.0) n = 30 11.9 (8.1) n=47 <0.01
AET PHI off PPI, n=42 3.3 (4.4) 1.7 (1.7) n = 31 8.0 (6.3) n = 11 <0.01